Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22337232 | 0.83 | KMT2A (0.83) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL26135108 | 0.79 | MAPT (0.80) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL31653615 | 0.79 | MAPT (0.80) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL26115021 | 0.79 | MAPT (0.80) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL1444576 | 0.71 | MAPT (0.69) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL11961917 | 0.71 | MAPT (0.69) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL22892508 | 0.70 | MAPT (0.71) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL26135935 | 0.70 | KMT2A (0.65) | KMT2AALDH1A1KDM4EMAPTAKR1C3 | |
| SCHEMBL26135049 | 0.70 | KMT2A (0.65) | KMT2AALDH1A1KDM4EMAPTAKR1C3 | |
| SCHEMBL26136383 | 0.70 | KMT2A (0.65) | KMT2AALDH1A1KDM4EMAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194336-A1 | P38 MAPK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ALLINKY BIOPHARMA (ES) | 2016-07-07 | — | — | US | disclosed |
| US-20160194336-A1 | P38 MAPK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ALLINKY BIOPHARMA (ES) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194336-A1 | P38 MAPK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MAPK14, MAPK1, MAPK11 | KMT2A 3887/4885SMN1; SMN2 1987/4885ALDH1A1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.